- current active treatment with medications contraindicated for receipt of investigational product. - require chemotherapy or urgent systemic therapy for active cancer that cannot be withheld. - no remaining available therapies for advanced or metastatic malignancies. - participation in another clinical study with therapeutic intent for covid-19 - require artificial ventilation at screening. - life expectancy less than 6 months. - medical conditions that make it unsafe to receive investigational product (for example, heart attack in the last 6 mos, unstable angina, uncontrolled arrhythmia, heart failure class 3/4, qtc interval > 480 msec; known bleeding disorders, stroke or intracranial hemorrhage in the last 6 mos; active hbv, hcv or history of hiv; gi malabsorption syndrome, small bowel resection, poorly controlled ibs; untreated/actively progressing known cns lesions). - receipt of radiation therapy to the lung or mediastinum for treatment of covid-19

- current active treatment with medications contraindicated for receipt of investigational product. - require chemotherapy or urgent systemic therapy for active cancer that cannot be withheld. - no remaining available therapies for advanced or metastatic malignancies. - participation in another clinical study with therapeutic intent for covid-19 - require artificial ventilation at screening. - life expectancy less than 6 months. - medical conditions that make it unsafe to receive investigational product (for example, heart attack in the last 6 mos, unstable angina, uncontrolled arrhythmia, heart failure class 3/4, qtc interval > 480 msec; known bleeding disorders, stroke or intracranial hemorrhage in the last 6 mos; active hbv, hcv or history of hiv; gi malabsorption syndrome, small bowel resection, poorly controlled ibs; untreated/actively progressing known cns lesions). - receipt of radiation therapy to the lung or mediastinum for treatment of covid-19

- current active treatment with medications contraindicated for receipt of investigational product. - require chemotherapy or urgent systemic therapy for active cancer that cannot be withheld. - no remaining available therapies for advanced or metastatic malignancies. - participation in another clinical study with therapeutic intent for covid-19, except where patients are receiving hydroxychloroquine or chloroquine and/or azithromycin and/or remdesivir. - require artificial ventilation at screening. - life expectancy less than 6 months. - advanced healthcare directive that includes do not intubate (dni) or do not resuscitate (dnr) orders - medical conditions that make it unsafe to receive investigational product (for example, heart attack in the last 6 mos, unstable angina, uncontrolled arrhythmia, heart failure class 3/4, qtc interval > 480 msec; known bleeding disorders, stroke or intracranial hemorrhage in the last 6 mos; active hbv, hcv or history of hiv; gi malabsorption syndrome, small bowel resection, poorly controlled ibs; untreated/actively progressing known cns lesions). - receipt of radiation therapy to the lung or mediastinum for treatment of covid-19

- current active treatment with medications contraindicated for receipt of investigational product. - require chemotherapy or urgent systemic therapy for active cancer that cannot be withheld. - no remaining available therapies for advanced or metastatic malignancies. - participation in another clinical study with therapeutic intent for covid-19, except where patients are receiving hydroxychloroquine or chloroquine and/or azithromycin and/or remdesivir. - require artificial ventilation at screening. - life expectancy less than 6 months. - advanced healthcare directive that includes do not intubate (dni) or do not resuscitate (dnr) orders - medical conditions that make it unsafe to receive investigational product (for example, heart attack in the last 6 mos, unstable angina, uncontrolled arrhythmia, heart failure class 3/4, qtc interval > 480 msec; known bleeding disorders, stroke or intracranial hemorrhage in the last 6 mos; active hbv, hcv or history of hiv; gi malabsorption syndrome, small bowel resection, poorly controlled ibs; untreated/actively progressing known cns lesions). - receipt of radiation therapy to the lung or mediastinum for treatment of covid-19